Are pyridazines privileged structures?

Wermuth, 1965, Bull. Soc. Chim. Fr., 2242

Wermuth, 1966, Bull. Soc. Chim. Fr., 1435

Laborit, 1965, Agressologie, 6, 401

G. Heinisch and H.Frank , Pharmacologically Active Pyridazines. Part 1 , in Progress in Medicinal Chemistry , ed. G. P. Ellis and G. B. West , Elsevier , Amsterdam , 1990 , vol. 27 , pp. 1–49

G. Heinisch and H.Kopelenk-Frank , Pharmacologically Active Pyridazines. Part 2 , in Progress in Medicinal Chemistry , ed. G. P. Ellis and D. K. Luscombe , Elsevier , Amsterdam , 1992 , vol. 29 , pp. 141–183

Grote, 1988, J. Antibiot., 41, 595, 10.7164/antibiotics.41.595

Bockholt, 1994, Angew. Chem., Int. Ed. Engl., 33, 1648, 10.1002/anie.199416481

Winter, 2009, Angew. Chem., Int. Ed., 48, 767, 10.1002/anie.200805140

Nakamura, 1994, Bull. Chem. Soc. Jpn., 67, 2151, 10.1246/bcsj.67.2151

Hughes, 1989, J. Org. Chem., 54, 3260, 10.1021/jo00275a007

Pettibone, 1989, Endocrinology, 125, 117, 10.1210/endo-125-1-217

Schneider, 1948, J. Am. Chem. Soc., 70, 627, 10.1021/ja01182a058

Chapman, 1991, J. Mol. Biol., 217, 455, 10.1016/0022-2836(91)90749-V

Komeda, 2003, J. Med. Chem., 46, 1210, 10.1021/jm020004+

Gleave, 2010, Bioorg. Med. Chem. Lett., 20, 465, 10.1016/j.bmcl.2009.11.117

Heinisch, 1996, J. Med. Chem., 39, 4058, 10.1021/jm960341g

Rognan, 1990, Eur. J. Pharmacol., 189, 59, 10.1016/0922-4106(90)90230-U

Wermuth, 1986, Trends Pharmacol. Sci., 7, 421, 10.1016/0165-6147(86)90408-6

Wermuth, 1987, J. Med. Chem., 30, 239, 10.1021/jm00385a003

Hamdouchi, 2003, J. Med. Chem., 46, 4333, 10.1021/jm020583i

Fox, 2010, Bioorg. Med. Chem. Lett., 20, 6030, 10.1016/j.bmcl.2010.08.066

Dyck, 2006, J. Med. Chem., 49, 3753, 10.1021/jm051263c

Giovannoni, 2006, J. Med. Chem., 49, 5363, 10.1021/jm060265+

B. E. Evans , K. E.Rittle , M. G.Bock , R. M.DiPardo , R. M.Freidinger , W. L.Whitter , G. F.Lundell , D. F.Veber , P. S.Anderson , R. S. L.Chang , V. J.Lotti , D. J.Cerino , T. B. P. J. K.Chen , K. A.Kunkel , J. P.Springer and J.Hirshfield , Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists , J. Med. Chem. , 1988 , 31 , 22352246

K. Russell and W. F.Michne , The Value of Chemical Genetics in Drug Discovery , in Chemogenomics in Drug Discovery , ed. H. Kubinyi and G. Müller , VCH , 2004 , pp. 69–96

A. Kolinsky , Lead-Likeness and Drug-Likeness , in The Practice of Medicinal Chemistry , ed. C. G. Wermuth , Elsevier , San Diego , 2008 , pp. 244–254